FDA Approves GLP-1 pill, Foundayo, for Weight Loss

Translate to Spanish or other 102 languages!

The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problem. Image for illustration purposes
The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problem. Image for illustration purposes
- Advertisement -

Medical News Today

The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problems.

This approval makes Eli Lilly’s oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug available in pill form, after Wegovy, which gained approval in December 2025.

- Advertisement -

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/fda-approves-oral-glp-1-pill-foundayo-for-weight-loss

Information source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Health Information Technology Instructor Adds Advanced Certification at STC

Nearly a decade after launching her career in health information, South Texas College faculty member Beatriz Martinez-Leal has come full circle, drawing on years of industry experience to shape the next generation of healthcare professionals.

STHS Contributes $5,000 to Texas A&M McAllen Nursing Program

Texas Border Business A strong healthcare workforce begins with quality education and...

Preventing Carbon Monoxide Exposure

Mega Doctor News CLEVELAND CLINIC - With cooler weather here to stay and...

STHS Heart Ranked Among Texas’ Top 5 Hospitals for Coronary Intervention

For Valley residents, STHS Heart continues to distinguish itself through nationally recognized heart and vascular services and a commitment to delivering high-quality, compassionate care close to home.
- Advertisement -